このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発または難治性皮膚 T 細胞リンパ腫または成人 T 細胞白血病/リンパ腫の治療のためのサードパーティのナチュラル キラー細胞およびモガムリズマブ

2026年11月10日 更新者:John Reneau

皮膚T細胞リンパ腫または成人T細胞白血病/リンパ腫の患者におけるモガムリズマブと組み合わせた、IL-21拡張された市販のサードパーティナチュラルキラー(NK)細胞のパイロット第I相試験

This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

PRIMARY OBJECTIVE:

I. To determine safety, tolerability, and determine the maximum tolerated dose (MTD) of IL-21 expanded, off the shelf, third-party natural killer (NK) cells and mogamulizumab in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL).

SECONDARY OBJECTIVES:

I. To determine the overall response rate (ORR), progression free survival (PFS) and overall survival (OS) in same patient population treated with IL-21 expanded, off the shelf, third-party NK cells and mogamulizumab.

II. To determine impact of treatment on quality of life (QOL) by skindex-16 score.

CORRELATIVE OBJECTIVES:

I. To study CCR4 expression in lymphoma cells. II. To study serum cytokine levels. III. To study trafficking of third-party NK cells to skin and tissues. IV. To study the persistence of IL-21 expanded, off the shelf, third-party NK cells by chimerism studies.

OUTLINE: This is a dose-escalation study of natural killer cells.

Patients receive mogamulizumab intravenously (IV) over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion every 2 weeks for six infusions total starting on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 28-35 days and then every 3 months for 2 years.

研究の種類

介入

入学 (推定)

12

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • 募集
        • Ohio State University Comprehensive Cancer Center
        • コンタクト:
        • 主任研究者:
          • John C. Reneau, MD, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Able to understand and voluntarily sign an informed consent form

  • Age >= 18 years at the time of signing the informed consent form

  • Able to adhere to the study visit schedule and other protocol requirements

  • Biopsy-proven, measurable, stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma after 1 prior line of systemic therapy

    • Note: extracorporeal photopheresis will be considered a systemic therapy for this study
  • Patients with large cell transformation of cutaneous T cell lymphoma are eligible

  • Patients with adult T-cell leukemia/lymphoma (ATLL) of any stage and any subtypes. Patient must have had at least one standard chemotherapy and measurable disease at the time of enrollment

  • Patients who relapsed after autologous or allogeneic stem cell transplant are eligible

  • All cancer therapy, including radiation, topical steroid, and chemotherapy must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study. The only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (> 60 days) without change. These patients may continue use of either systemic steroids (equivalent to < 10 mg per day of prednisone) or topical steroids if the frequency and dosage steroids has not changed for 21 days prior to the study. These participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be tapered or discontinued. Patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (ie, steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agents

  • Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 at study entry

  • Absolute neutrophil count >= 1000/mm^3

  • Platelet count >= 50,000/mm^3

  • Total bilirubin =< 2 x upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and Alanine Aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN

    • AST (SGOT) and ALT (SGPT) =< 5 x ULN in patients with documented hepatic involvement by lymphoma
  • Calculated creatinine clearance >= 50 ml/min (by the Crockroft-Gault equation)

  • Disease free of prior malignancies for >= 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. Patients with early stage of prostate cancer under clinical surveillance without therapy are eligible. Patients with B-cell lymphomas treated with curative intent, and in remission for at least 2 years, may be in included (after discussion with principal investigator [PI])

  • Negative serum pregnancy test at the time of enrollment for females of childbearing potential. Women who can get pregnant and men with partners who can become pregnant will be asked to practice a highly effective method of birth control while participating in the study that is considered medically acceptable by the study doctor.

  • Life expectancy >= 90 days

Exclusion Criteria:

  • Investigational therapies in the 2 weeks prior to beginning treatment on trial
  • Patients with active central nervous system (CNS) involvement with lymphoma
  • Patients with known human immunodeficiency virus (HIV) infection with CD4 < 350
  • Patients who had solid organ transplants
  • Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), or active hepatitis C infection based on positive PCR. Patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent and be willing to undergo monthly hepatitis B DNA PCR testing
  • Present or history of progressive multifocal leukoencephalopathy (PML)
  • Active grade II-IV acute or extensive chronic graft versus (vs.) host disease (GVHD)
  • Patients may take steroids at any dose for disease control up to 24 hours prior to study enrollment. Steroids must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study, per inclusion criteria above. Topical steroids are allowed for CTCL patients
  • Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
  • A cardiovascular disability status of New York Heart Association class >= 2
  • History of severe allergic reactions to humanized monoclonal antibodies
  • History of other malignancy that could affect compliance with the protocol or interpretation of results. Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible. Patients with early stage of prostate cancer under clinical surveillance without therapy are eligible
  • Known hypersensitivity to any of the study drugs or analogs
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy
  • Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
  • Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
  • Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis
  • Receiving immunosuppressive therapy
  • Prior therapy with mogamulizumab unless stopped previously for reasons other than progression or toxicity.
  • Pregnant or lactating, or intending to become pregnant during the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (mogamulizumab, chemotherapy, NK cells)

Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.

Ancillary studies

他の名前:
  • 生活の質の評価

Given IV

他の名前:
  • シトキサン
  • CTX
  • (-)-シクロホスファミド
  • 2H-1,3,2-オキサザホスホリン、2-[ビス(2-クロロエチル)アミノ]テトラヒドロ-、2-オキシド、一水和物
  • カルロキサン
  • シクロホスファミダ
  • シクロホスファミド
  • シクロキサール
  • クラフェン
  • CP一水和物
  • サイクロセル
  • シクロスブラスチン
  • シクロブラスチン
  • シクロホスファム
  • シクロホスファミド一水和物
  • シクロホスファミダム
  • シクロホスファン
  • シクロホスファナム
  • シクロスチン
  • サイトホスファン
  • シトホスファン
  • フォスファセロン
  • ジェノクサル
  • ジェヌサル
  • レドキシン
  • ミトキサン
  • ネオサー
  • レビミューン
  • WR-138719

Ancillary studies

Given IV

他の名前:
  • フルラドサ

Given IV

他の名前:
  • KW-0761
  • 免疫グロブリン G1、抗 (CC ケモカイン受容体 CCR4) (ヒト-マウス モノクローナル KW-0761 重鎖)、ヒト-マウス モノクローナル KW-0761 カッパ鎖とのジスルフィド、二量体
  • KM8761
  • モガムリズマブ-kpkc
  • ポテリジオ

Given via infusion

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of adverse events
時間枠:Up to day 84

Toxicities will be captured by Common Terminology Criteria for Adverse Events version 5. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. The incidence of severe adverse events or toxicities will be described. Will assess the proportion of patients who experience grade 3 or higher non-hematologic toxicity.

Up to day 84

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall response rate (ORR)
時間枠:Up to 4 months

Will be summarized in a descriptive manner. The ORR will be calculated as the proportion of patients who achieve complete response /partial response, and provided with 95% confidence interval.

Up to 4 months
Progression free survival
時間枠:From start of study treatment (from the first dose mogamulizumab [moga]) to first documentation of tumor progression (including radiographic and clinical progression) or to death due to any cause, whichever comes first, assessed up to 2 years

Will be estimated using the method of Kaplan-Meier.

From start of study treatment (from the first dose mogamulizumab [moga]) to first documentation of tumor progression (including radiographic and clinical progression) or to death due to any cause, whichever comes first, assessed up to 2 years
Overall survival
時間枠:From start of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the patient is known to be alive, whichever comes first, assessed up to 2 years

Will be estimated using the method of Kaplan-Meier.

From start of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the patient is known to be alive, whichever comes first, assessed up to 2 years
Natural Killer (NK)-cell numerical expansion in vivo
時間枠:Baseline to day 84

Peripheral blood will be obtained before therapy, during the NK cell treatment period (day +42), after NK cell treatment (day +84), and at the time of progression. Donor NK-cell expansion will be defined as an absolute circulating donor-derived NK cell count that increases above the post-infusion level. Standard chimerism methods will be employed to determine origin and number of circulating NK cells.

Baseline to day 84
Analysis of cytokine levels
時間枠:Baseline to day 84

Peripheral blood will be obtained before therapy, during the NK cell treatment period (day +42), after NK cell treatment (day +84), and at the time of relapse. Cytokine levels will be reported as absolute values and will be correlated with response to treatment and skindex-16 scores.

Baseline to day 84
Quality of life analysis
時間枠:Baseline to day 84

Skindex-16 questionnaires will be obtained before therapy, during the NK cell treatment period (day +42), and after NK cell treatment (day +84, and every 2 months while on moga treatment). Skindex will be reported as total and specific domain scores, and described using graphical manners to show the pattern of change over treatment course.

Baseline to day 84

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:John C Reneau, MD, PhD、Ohio State University Comprehensive Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年5月6日

一次修了 (推定)

2027年7月30日

研究の完了 (推定)

2028年7月30日

試験登録日

最初に提出

2021年4月13日

QC基準を満たした最初の提出物

2021年4月13日

最初の投稿 (実際)

2021年4月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • OSU-20103
  • NCI-2021-01375 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。